Adma Biologics (ADMA) Total Non-Current Liabilities (2011 - 2025)

Adma Biologics (ADMA) has 14 years of Total Non-Current Liabilities data on file, last reported at $146.9 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 5.47% year-over-year to $146.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146.9 million (up 5.47% YoY) and the FY2025 annual result came in at $146.9 million, up 5.47% from the prior year.
• Total Non-Current Liabilities advanced to $146.9 million in Q4 2025, from $137.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $199.8 million in Q3 2022 to a low of $121.2 million in Q2 2021.
• A 5-year average of $165.9 million and a median of $170.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 50.32% — and 2025, when it slumped 30.3%.
• Tracing ADMA's Total Non-Current Liabilities over 5 years: stood at $134.7 million in 2021, then surged by 45.63% to $196.1 million in 2022, then declined by 1.32% to $193.6 million in 2023, then slipped by 28.03% to $139.3 million in 2024, then rose by 5.47% to $146.9 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $146.9 million (Q4 2025), $137.4 million (Q3 2025), and $160.1 million (Q2 2025), per Business Quant data.